MedTrace Logo

Phase 2b Controlled Study of Dosing Techniques - Part B

NCT07161011 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-03-27

No results posted yet for this study

Summary

Double-masked, dose-response of two concentrations of IVW-1001

Conditions

  • Dry Eye

Interventions

DRUG

IVW-1001 Ophthalmic Eyelid Wipe 0.2%

Low dose

DRUG

IVW-1001 Ophthalmic Eyelid Wipe 0.4%

High dose

Sponsors & Collaborators

  • IVIEW Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-08
Primary Completion
2025-11-03
Completion
2025-11-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07161011 on ClinicalTrials.gov